Latest Multicell Techs Inc (MCET) Headlines M
Post# of 45
Posted On: 03/10/2014 12:46:37 PM
Latest Multicell Techs Inc (MCET) Headlines
MultiCell Technologies Seeks Patent for Cancer-Fighting Technology
ACCESSWIRE - Tue Mar 04, 9:03AM CST
MultiCell Technologies Inc. (OTCQB: MCET) stock volume soared Mar. 3, with 41,190,256 shares changing hands, significantly higher than its three-month average volume of 30,444,778 shares.
MultiCell Technologies Inc files patent application for new class of RNA Therapeutics, VSRNAs
M2 - Thu Jan 16, 4:40AM CST
Biopharmaceutical company MultiCell Technologies Inc (OTC BB:MCET.OB) reported on Wednesday the submission of a US provisional patent application covering the composition of matter, biological targets, mechanism of action, methods and formulations to achieve targeted tumor cell death.
MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics
PR Newswire - Wed Jan 15, 7:39AM CST
MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) has filed a U.S. provisional patent application concerning composition of matter, biological targets, mechanism of action, methods and formulations to achieve targeted tumor cell death.
MultiCell Technologies Files U.S. Patent Application for Targeted Delivery of MCT-485, a Noncoding miRNA for Cancer Treatment
PR Newswire - Wed Nov 13, 7:13AM CST
MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) has filed a second U.S. patent application concerning methods and formulations to achieve targeted tumor cell death. MCT-485 is a noncoding double stranded micro RNA (miRNA) which has demonstrated oncolytic and immune stimulating activity in in vitro models of hepatocellular carcinoma. MCT-485 is currently being evaluated in animal models of hepatocellular carcinoma.
Breast Cancer - Pipeline Review, H2 2013 Reviews Key Players Involved in the Therapeutic Development for Breast Cancer
M2 - Tue Nov 05, 10:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfkggb/breast_cancer) has announced the addition of the "Breast Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Breast Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Breast Cancer. Breast Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Breast Cancer. - A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Breast Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Some of the Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Kyowa Hakko Kirin Co., Ltd. - Celsion Corporation - Biogen Idec Inc. - Amgen Inc. - A&G Pharmaceutical, Inc. - Novartis AG - Aphios Corporation - Biocon Limited - Chong Kun Dang Pharmaceutical - Marshall Edwards, Inc. - Basilea Pharmaceutica Ltd. - Bionomics Limited - MultiCell Technologies, Inc. - Neuren Pharmaceuticals Limited - Natco Pharma Limited - Sareum Holdings plc - TRACON Pharmaceuticals, Inc. - Nexgenix Pharmaceuticals, LLC - DEKK-TEC, Inc. - Regulon Inc. - AUS Bio Limited - EirGen Pharma Ltd. - Epeius Biotechnologies Corporation - Ampio Pharmaceuticals, Inc. - CytomX, LLC. For more information visit http://www.researchandmarkets.com/research/hf...ast_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OTC Daily Alert Stock Watch - MultiCell Technologies, Inc. (OTCQB: MCET)
WorldStockWire - Thu Sep 05, 4:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
MultiCell Technologies and Genisphere Evaluate Targeted Delivery of MCT-485, a Noncoding miRNA for the Treatment of Cancer
PR Newswire - Tue Aug 06, 7:00AM CDT
MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) and Genisphere LLC will collaborate on the development of targeted MCT-485 nanoparticle therapeutics for the treatment of liver cancer. MCT-485 is a noncoding double stranded micro RNA (miRNA) which has demonstrated oncolytic and immune stimulating activity in in vitro models of hepatocellular carcinoma.
MultiCell Technologies Files U.S. Patent Application for Targeted Delivery of Noncoding Micro RNAs for the Treatment of Liver Cancer
PR Newswire - Thu May 16, 7:00AM CDT
MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) is pleased to announce the filing of a U.S. patent application concerning methods and formulations to achieve targeted tumor cell death. MCT-485 is a noncoding double stranded micro RNA (miRNA) which has demonstrated oncolytic and immune stimulating activity in in vitro models of hepatocellular carcinoma.
MultiCell Technologies and Federal National Mortgage Association Review: (OTCQB: MCET), (OTCQB: FNMA)
ACCESSWIRE-TNW - Sun Mar 03, 4:29PM CST
New York (March 3rd, 2013) - MultiCell Technologies, Inc. (OTCQB: MCET) Files SEC form 10-K, Annual Report.
Medical Marijuana and MultiCell Technologies News: (OTC Pink: MJNA), (OTCQB: MCET)
ACCESSWIRE-TNW - Fri Mar 01, 1:21AM CST
New York (March 1st, 2013) - Medical Marijuana, Inc. (OTC Pink: MJNA) a leading cannabis and hemp industry innovator provided a comprehensive update to shareholders on the state of the medical cannabis and hemp industry. Many legislative actions have occurred, particularly since the November elections, which are providing significant positive momentum in our rapidly expanding markets.
China Teletech Holding and MultiCell Technologies Trend Analysis Reports: (OTCQB: CNCT), (OTCQB: MCET)
ACCESSWIRE-TNW - Tue Feb 26, 1:58AM CST
New York (February 26th, 2013) - China Teletech Holding, Inc. (OTCQB: CNCT) last traded at $0.215, down $-0.069 or 24.30%. The stock has a 52 week range of $0.00 - $0.47. In the last session the stock traded a volume of 26.58M versus a 30 day average of 843,675.
AMR Corp Announcement & MultiCell Technologies Bullish Momentum: (OTCQB: AAMRQ), (OTCQB: MCET)
ACCESSWIRE-TNW - Wed Feb 20, 12:06AM CST
New York (February 20th, 2013) - AMR Corporation (OTCQB: AAMRQ), the parent company of American Airlines, Inc., and US Airways Group, Inc. (LCC) announced last week that the boards of directors of both companies have unanimously approved a definitive merger agreement under which the companies will combine to create a premier global carrier, which will have an implied combined equity value of approximately $11 billion based on the price of US Airways' stock as of February 13, 2013.
MultiCell Technologies presents abstract at 2012 ASCB Meeting
M2 - Thu Dec 27, 8:39AM CST
MultiCell Technologies Inc (OTCBB: MCET), a clinical-stage biopharmaceutical company, said on Wednesday that at the 2012 American Society for Cell Biology (ASCB) Annual Meeting, being held in San Francisco, California, Simona Bot, MD on Tuesday presented preclinical research results in an abstract titled 'Short Synthetic Double Stranded RNA with Dual Activity - Oncolytic and Immune Modulatory - for Hepatocellular Carcinoma'.
MultiCell Technologies Delivered Presentation at 2012 ASCB Meeting
PR Newswire - Wed Dec 26, 7:00AM CST
MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) presented at the 2012 American Society for Cell Biology® (ASCB®) Annual Meeting in San Francisco, CA, on Tuesday, December 18. Simona Bot, M.D. presented preclinical research results in an abstract titled "Short Synthetic Double Stranded RNA with Dual Activity - Oncolytic and Immune Modulatory - for Hepatocellular Carcinoma."
MultiCell Technologies Seeks Patent for Cancer-Fighting Technology
ACCESSWIRE - Tue Mar 04, 9:03AM CST
MultiCell Technologies Inc. (OTCQB: MCET) stock volume soared Mar. 3, with 41,190,256 shares changing hands, significantly higher than its three-month average volume of 30,444,778 shares.
MultiCell Technologies Inc files patent application for new class of RNA Therapeutics, VSRNAs
M2 - Thu Jan 16, 4:40AM CST
Biopharmaceutical company MultiCell Technologies Inc (OTC BB:MCET.OB) reported on Wednesday the submission of a US provisional patent application covering the composition of matter, biological targets, mechanism of action, methods and formulations to achieve targeted tumor cell death.
MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics
PR Newswire - Wed Jan 15, 7:39AM CST
MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) has filed a U.S. provisional patent application concerning composition of matter, biological targets, mechanism of action, methods and formulations to achieve targeted tumor cell death.
MultiCell Technologies Files U.S. Patent Application for Targeted Delivery of MCT-485, a Noncoding miRNA for Cancer Treatment
PR Newswire - Wed Nov 13, 7:13AM CST
MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) has filed a second U.S. patent application concerning methods and formulations to achieve targeted tumor cell death. MCT-485 is a noncoding double stranded micro RNA (miRNA) which has demonstrated oncolytic and immune stimulating activity in in vitro models of hepatocellular carcinoma. MCT-485 is currently being evaluated in animal models of hepatocellular carcinoma.
Breast Cancer - Pipeline Review, H2 2013 Reviews Key Players Involved in the Therapeutic Development for Breast Cancer
M2 - Tue Nov 05, 10:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfkggb/breast_cancer) has announced the addition of the "Breast Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Breast Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Breast Cancer. Breast Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Breast Cancer. - A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Breast Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Some of the Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Kyowa Hakko Kirin Co., Ltd. - Celsion Corporation - Biogen Idec Inc. - Amgen Inc. - A&G Pharmaceutical, Inc. - Novartis AG - Aphios Corporation - Biocon Limited - Chong Kun Dang Pharmaceutical - Marshall Edwards, Inc. - Basilea Pharmaceutica Ltd. - Bionomics Limited - MultiCell Technologies, Inc. - Neuren Pharmaceuticals Limited - Natco Pharma Limited - Sareum Holdings plc - TRACON Pharmaceuticals, Inc. - Nexgenix Pharmaceuticals, LLC - DEKK-TEC, Inc. - Regulon Inc. - AUS Bio Limited - EirGen Pharma Ltd. - Epeius Biotechnologies Corporation - Ampio Pharmaceuticals, Inc. - CytomX, LLC. For more information visit http://www.researchandmarkets.com/research/hf...ast_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OTC Daily Alert Stock Watch - MultiCell Technologies, Inc. (OTCQB: MCET)
WorldStockWire - Thu Sep 05, 4:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
MultiCell Technologies and Genisphere Evaluate Targeted Delivery of MCT-485, a Noncoding miRNA for the Treatment of Cancer
PR Newswire - Tue Aug 06, 7:00AM CDT
MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) and Genisphere LLC will collaborate on the development of targeted MCT-485 nanoparticle therapeutics for the treatment of liver cancer. MCT-485 is a noncoding double stranded micro RNA (miRNA) which has demonstrated oncolytic and immune stimulating activity in in vitro models of hepatocellular carcinoma.
MultiCell Technologies Files U.S. Patent Application for Targeted Delivery of Noncoding Micro RNAs for the Treatment of Liver Cancer
PR Newswire - Thu May 16, 7:00AM CDT
MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) is pleased to announce the filing of a U.S. patent application concerning methods and formulations to achieve targeted tumor cell death. MCT-485 is a noncoding double stranded micro RNA (miRNA) which has demonstrated oncolytic and immune stimulating activity in in vitro models of hepatocellular carcinoma.
MultiCell Technologies and Federal National Mortgage Association Review: (OTCQB: MCET), (OTCQB: FNMA)
ACCESSWIRE-TNW - Sun Mar 03, 4:29PM CST
New York (March 3rd, 2013) - MultiCell Technologies, Inc. (OTCQB: MCET) Files SEC form 10-K, Annual Report.
Medical Marijuana and MultiCell Technologies News: (OTC Pink: MJNA), (OTCQB: MCET)
ACCESSWIRE-TNW - Fri Mar 01, 1:21AM CST
New York (March 1st, 2013) - Medical Marijuana, Inc. (OTC Pink: MJNA) a leading cannabis and hemp industry innovator provided a comprehensive update to shareholders on the state of the medical cannabis and hemp industry. Many legislative actions have occurred, particularly since the November elections, which are providing significant positive momentum in our rapidly expanding markets.
China Teletech Holding and MultiCell Technologies Trend Analysis Reports: (OTCQB: CNCT), (OTCQB: MCET)
ACCESSWIRE-TNW - Tue Feb 26, 1:58AM CST
New York (February 26th, 2013) - China Teletech Holding, Inc. (OTCQB: CNCT) last traded at $0.215, down $-0.069 or 24.30%. The stock has a 52 week range of $0.00 - $0.47. In the last session the stock traded a volume of 26.58M versus a 30 day average of 843,675.
AMR Corp Announcement & MultiCell Technologies Bullish Momentum: (OTCQB: AAMRQ), (OTCQB: MCET)
ACCESSWIRE-TNW - Wed Feb 20, 12:06AM CST
New York (February 20th, 2013) - AMR Corporation (OTCQB: AAMRQ), the parent company of American Airlines, Inc., and US Airways Group, Inc. (LCC) announced last week that the boards of directors of both companies have unanimously approved a definitive merger agreement under which the companies will combine to create a premier global carrier, which will have an implied combined equity value of approximately $11 billion based on the price of US Airways' stock as of February 13, 2013.
MultiCell Technologies presents abstract at 2012 ASCB Meeting
M2 - Thu Dec 27, 8:39AM CST
MultiCell Technologies Inc (OTCBB: MCET), a clinical-stage biopharmaceutical company, said on Wednesday that at the 2012 American Society for Cell Biology (ASCB) Annual Meeting, being held in San Francisco, California, Simona Bot, MD on Tuesday presented preclinical research results in an abstract titled 'Short Synthetic Double Stranded RNA with Dual Activity - Oncolytic and Immune Modulatory - for Hepatocellular Carcinoma'.
MultiCell Technologies Delivered Presentation at 2012 ASCB Meeting
PR Newswire - Wed Dec 26, 7:00AM CST
MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) presented at the 2012 American Society for Cell Biology® (ASCB®) Annual Meeting in San Francisco, CA, on Tuesday, December 18. Simona Bot, M.D. presented preclinical research results in an abstract titled "Short Synthetic Double Stranded RNA with Dual Activity - Oncolytic and Immune Modulatory - for Hepatocellular Carcinoma."
(0)
(0)Multicell Techs Inc (MCET) Stock Research Links
Scroll down for more posts ▼